NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
NeuroMetrix Trading Down 10.2 %
Shares of NASDAQ:NURO opened at $3.35 on Wednesday. The stock has a fifty day simple moving average of $3.65 and a 200-day simple moving average of $3.89. NeuroMetrix has a twelve month low of $2.70 and a twelve month high of $19.74. The stock has a market capitalization of $23.89 million, a PE ratio of -5.78 and a beta of 2.60.
NeuroMetrix (NASDAQ:NURO - Get Rating) last announced its earnings results on Thursday, July 21st. The medical device company reported ($0.17) earnings per share for the quarter. The business had revenue of $2.14 million for the quarter. NeuroMetrix had a negative return on equity of 16.02% and a negative net margin of 45.76%.